New cocktail aims to make immunotherapy work for common colorectal cancer

This phase 2 trial is testing whether a combination of chemotherapy (mFOLFOX6), a targeted therapy (bevacizumab), and an immunotherapy (PD-1 inhibitor) can help people with a specific type of locally advanced colorectal cancer called microsatellite stable (MSS). Unlike other colorectal cancers, MSS tumors usually do not respond to immunotherapy alone. The study includes about 42 participants with stage T4NxM0 disease, where the tumor is growing through the bowel wall and may involve nearby lymph nodes. The main goal is to see if this combination can lead to a complete disappearance of the cancer at the time of surgery.